Tamoxifen

Tamoxifen blocks estrogen-receptor signaling in breast tissue and is used to treat or reduce the risk of hormone-sensitive breast cancer, while exerting estrogen-like effects in some other tissues that explain both benefits and serious risks.

Tamoxifen is a prodrug whose active metabolites, especially endoxifen, bind estrogen receptors. In breast tissue, the drug-receptor complex reduces estrogen-dependent gene transcription and cell proliferation. In other tissues, tamoxifen can have partial estrogen-agonist effects, contributing to bone and lipid effects as well as uterine and thromboembolic risks. [M1, M2]

CYP2D6 and CYP3A enzymes contribute to formation of active metabolites. Genetic variation, adherence, interacting medicines, menopausal status, and other factors can alter exposure, but the clinical value of routine CYP2D6-guided prescribing remains debated. [M1, M7]

Tamoxifen is principally a breast-cancer medicine. The U.S. product labeling and NCI summary include the following settings; exact duration and sequencing are intentionally omitted. [M1, M2]

ER-positive metastatic breast cancer in adults, including women and men. [M1, M2]

Adjuvant treatment of early-stage ER-positive breast cancer and reduction of contralateral breast cancer risk. [M1, M2, M3]

After surgery and radiation for ductal carcinoma in situ (DCIS), to reduce the risk of invasive breast cancer in selected adults. [M1, M2]

Reduction of breast-cancer incidence in selected adults at high risk after individualized assessment of benefits and harms. [M1, M2, M4]

Tamoxifen has been studied in other conditions, but off-label or investigational uses should not be included as routine cancer indications without a separate, clearly labeled evidence review. [M2]

Estrogen and progesterone receptors: ER is the central predictive biomarker. Tumors with meaningful ER expression are more likely to benefit from endocrine therapy. PR provides additional biological and prognostic information but is not a substitute for ER. Testing is usually performed by immunohistochemistry using validated breast-cancer pathology standards. [M2, M6]

CYP2D6 and endoxifen: CYP2D6 genotype and use of strong CYP2D6 inhibitors can lower endoxifen concentrations. Pharmacogenomic groups have proposed genotype-informed approaches, but clinical-outcome evidence has been inconsistent and routine testing is not universally recommended. CYP2D6 should be labeled as an emerging pharmacogenomic consideration, not a universally required companion diagnostic. [M1, M7]

Tamoxifen is taken orally as a tablet or oral solution. Different products may contain different inactive ingredients and measuring requirements. This profile omits dose, duration, and missed-dose instructions. [M1]

Common effects include hot flashes, vaginal discharge or bleeding, menstrual changes, nausea, fluid retention, fatigue, and mood or sexual symptoms. Men may experience hot flashes and sexual side effects. Symptoms and their severity vary, and some can also signal a more serious complication; new abnormal bleeding should not be dismissed as a routine side effect. [M1, M2]

Uterine malignancies, including endometrial cancer and rare uterine sarcoma; risk is especially relevant in people with a uterus and increases with exposure. [M1]

Venous thromboembolism, pulmonary embolism, and stroke. Risk-benefit considerations differ between treatment of established cancer and prevention in a healthy high-risk person. [M1]

Embryo-fetal harm; pregnancy must be avoided, and nonhormonal contraception may be advised according to the label and clinical context. [M1]

Liver abnormalities and rare serious hepatic events. [M1]

Eye problems, including cataracts and retinal changes. [M1]

Cytopenias and hypercalcemia, particularly in some people with metastatic disease involving bone. [M1]

Prompt evaluation of abnormal uterine bleeding, pelvic pain, pressure, or menstrual change. [M1]

Symptoms of DVT, pulmonary embolism, or stroke, such as unilateral leg swelling, sudden chest pain or breathlessness, or acute neurologic deficit. [M1]

Periodic liver-function tests and blood counts according to clinical context. [M1]

Eye evaluation for visual symptoms and routine age-appropriate ophthalmic care. [M1]

Pregnancy assessment and reproductive counseling. [M1]

Adherence, menopausal symptoms, sexual health, bone health, and quality of life, because untreated side effects can reduce persistence with therapy. [M3]

Warfarin and other coumarin anticoagulants may have an enhanced anticoagulant effect; use is contraindicated in certain prevention/DCIS settings and requires close monitoring in treatment settings. [M1]

Anastrozole or letrozole should not simply be combined with tamoxifen; endocrine sequencing is a clinical decision. [M1]

Strong CYP2D6 inhibitors can lower endoxifen exposure. When an alternative medicine is clinically reasonable, the prescriber may prefer one with less CYP2D6 inhibition, but psychiatric or other essential therapy should not be changed abruptly. [M1, M7]

Strong CYP3A inducers may reduce tamoxifen exposure. [M1]

Tamoxifen is not expected to provide the same benefit in ER-negative breast cancer. [M2, M6]

Risk-reduction use lowers risk but does not prevent every breast cancer and carries serious harms; it requires formal individualized counseling. [M1, M4]

Choice between tamoxifen, aromatase inhibitors, ovarian suppression, or another endocrine strategy depends on menopausal status, recurrence risk, prior therapy, tolerability, bone health, fertility goals, and comorbidities. [M2]

CYP2D6 genotype or endoxifen level should not be presented as a universally established requirement or as a standalone predictor of benefit. [M7]

Any vaginal bleeding in a postmenopausal patient requires evaluation; it should not be normalized on a patient-information page. [M1]

Endocrine resistance may arise through loss or alteration of ER signaling, changes in co-regulators, activation of HER2 or other growth-factor pathways, PI3K-AKT-MTOR or MAPK signaling, cell-cycle pathway activation, epigenetic change, clonal evolution, inadequate active-metabolite exposure, or nonadherence. [M8]

ESR1 mutations are an important mechanism of acquired resistance in metastatic ER-positive disease, particularly after aromatase-inhibitor exposure, but should not be described as the sole or universal cause of tamoxifen resistance. [M8]

ATLAS showed that extending tamoxifen beyond five years can further reduce recurrence and breast-cancer mortality in selected ER-positive early breast cancer, while increasing cumulative uterine and thromboembolic risks. [M3]

Long-term prevention studies such as IBIS-I showed that risk reduction can persist after treatment, reinforcing the need for careful selection rather than universal preventive use. [M4]

Research continues on shorter or lower-dose strategies for selected noninvasive breast lesions, pharmacogenomic or endoxifen-guided treatment, and better management of vasomotor and sexual side effects. These approaches should not be represented as replacements for a prescribed regimen unless supported by the applicable guideline and clinician. [M7, M9]

Modern studies increasingly focus on choosing among multiple endocrine and targeted options based on recurrence risk and tumor genomics rather than treating all ER-positive cancers identically. [M8]

Regulatory indications and safety language are summarized primarily from U.S. FDA prescribing information. Approval status, testing requirements, formulations, and recommended use may differ in other countries or change after this document is published.